Sonoma Pharmaceuticals reported total revenues of $19.5 million for the fiscal year ended March 31, 2026, a 37% increase from $14.3 million in the prior year. The United States market saw significant growth, with revenues increasing by 117% to $5.7 million, attributed to increased sales of over-the-counter products and expanded distribution. International markets also contributed positively, with Europe up 25% to $6.9 million, Asia up 25% to $2.9 million, and Rest of World up 92% to $1.7 million. Latin America experienced a 20% decrease in revenue to $2.4 million, primarily due to the timing of customer orders for overflow manufacturing. Gross profit increased by 36% to $7.4 million, maintaining a gross profit margin of 38%, consistent with the previous year. Research and development expenses rose by 25% to $2.3 million, supporting new product releases. Selling, general, and administrative expenses increased by 3% to $7.6 million. The company reported a net loss of $3.2 million for the fiscal year, an improvement from a net loss of $3.5 million in the prior year. Cash and cash equivalents decreased to $2.4 million as of March 31, 2026, from $5.4 million in the prior year, with net cash used in operating activities at $3.9 million. The company raised $427,000 through the sale of common stock and received $374,000 from employee retention credits during the fiscal year.